Acute promyelocytic leukemia
RP Warrell Jr, H de The, ZY Wang… - New England Journal of …, 1993 - Mass Medical Soc
Discoveries in cancer research are rarely so exceptional that they both cause immediate
changes in the treatment of patients and dramatically advance our understanding of the …
changes in the treatment of patients and dramatically advance our understanding of the …
[PDF][PDF] Acute promyelocytic leukemia: from genetics to treatment
A CUTE PROMYELOCYTIC leukemia (APL) has aroused interest well beyond the
hematologic field during the last 4 to 5 years. Two features, both of which are unique to APL …
hematologic field during the last 4 to 5 years. Two features, both of which are unique to APL …
Characterization of acute promyelocytic leukemia cases lacking the classic t (15; 17): results of the European Working Party
D Grimwade, A Biondi, MJ Mozziconacci… - Blood, The Journal …, 2000 - ashpublications.org
Acute promyelocytic leukemia (APL) is typified by the t (15; 17), generating the PML-RARα
fusion and predicting a beneficial response to retinoids. However, a sizeable minority of APL …
fusion and predicting a beneficial response to retinoids. However, a sizeable minority of APL …
A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR …
The Spanish PETHEMA group designed a protocol for newly diagnosed PML/RAR-
positive acute promyelocytic leukemia (APL) in which induction and consolidation followed …
positive acute promyelocytic leukemia (APL) in which induction and consolidation followed …
A PMLRARα transgene initiates murine acute promyelocytic leukemia
D Brown, S Kogan, E Lagasse… - Proceedings of the …, 1997 - National Acad Sciences
The malignant cells of acute promyelocytic leukemia (APL) contain a reciprocal
chromosomal translocation that fuses the promyelocytic leukemia gene (PML) with the …
chromosomal translocation that fuses the promyelocytic leukemia gene (PML) with the …
Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid …
AK Burnett, D Grimwade, E Solomon… - Blood, The Journal …, 1999 - ashpublications.org
All-trans retinoic acid (ATRA) is an essential component of the treatment of acute
promyelocytic leukemia (APL), but the optimal timing and duration remain to be determined …
promyelocytic leukemia (APL), but the optimal timing and duration remain to be determined …
Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia
D Grimwade, F Lo Coco - Leukemia, 2002 - nature.com
Acute promyelocytic leukemia (APL) is characterized by a number of features that underpin
the need for rapid and accurate diagnosis and demand a highly specific treatment approach …
the need for rapid and accurate diagnosis and demand a highly specific treatment approach …
Therapy of molecular relapse in acute promyelocytic leukemia
FL Coco, D Diverio, G Avvisati, MC Petti… - Blood, The Journal …, 1999 - ashpublications.org
Fourteen patients with PML/RAR-positive acute promyelocytic leukemia (APL) were given
salvage therapy at the time of first molecular relapse. All patients had achieved first …
salvage therapy at the time of first molecular relapse. All patients had achieved first …
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
The prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not
firmly established and is of particular interest given the opportunities for targeted therapies …
firmly established and is of particular interest given the opportunities for targeted therapies …
5′ CpG island hypermethylation is associated with transcriptional silencing of the p21CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic …
J Roman-Gomez, JA Castillejo… - Blood, The Journal …, 2002 - ashpublications.org
The p21 is a downstream effector of p53/p73 and belongs to the CIP/KIP family of cyclin-
dependent kinase inhibitors (CDKIs). It is, therefore, a potential tumor suppressor gene and …
dependent kinase inhibitors (CDKIs). It is, therefore, a potential tumor suppressor gene and …